» Articles » PMID: 31337716

Sudan Ebolavirus VP35-NP Crystal Structure Reveals a Potential Target for Pan-Filovirus Treatment

Overview
Journal mBio
Specialty Microbiology
Date 2019 Jul 25
PMID 31337716
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The filoviruses are etiological agents of life-threatening hemorrhagic fever with high mortality rate and risk of potential outbreak. Among members of this family, the Ebola (EBOV), Sudan (SUDV), and Marburg (MARV) viruses are considered the most pathogenic for humans. The ebolavirus nucleoprotein (NP) is the most abundant protein in infected cells and is essential for viral transcription and replication; thus, it represents an attractive target for therapeutic intervention. Here, we present the structure of SUDV NP in complex with the amino-terminal portion of the phosphoprotein VP35 at 2.3 Å. This structure captures VP35 chaperoning SUDV NP in a monomeric and RNA-free state. This transient state has been proposed to be key to maintaining a pool of monomeric and RNA-free NPs prior to NP-NP polymerization and encapsidation of the viral RNA genome. This structure also reveals a newly visualized interaction between NP and VP35, a well-defined beta sheet that is not present in previous structures. Affinity binding assays demonstrate that this beta sheet is essential for maintaining the high-affinity interaction between VP35 and a hydrophobic pocket on SUDV NP, and electron microscopy indicates the importance of this binding interaction to the oligomeric state and assembly of NP in human cells. Complementary structure-directed mutagenesis identifies critical residues conserved across the filovirus family that could be targeted by broadly effective antivirals. Outbreaks of the filoviruses can be unpredictable in timing, location, and identity of the causative virus, with each of Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus reemerging in the last several years to cause human disease with 30 to 90% lethality. The 2014-2016 outbreak in particular, with nearly 30,000 patients, highlighted the ability of these viruses to emerge unexpectedly and spread rapidly. Two ebolavirus outbreaks have emerged this year, yet we still lack FDA-approved drugs with pan-filovirus activity to treat existing and emergent ebolaviruses. For all filoviruses, the interaction between the nucleoprotein and the phosphoprotein is essential for the virus life cycle and is a potential target for therapeutic intervention. In this report, we describe the crystal structure of the SUDV nucleoprotein with the interacting domain of the viral phosphoprotein, and we identify residues critical for high-affinity interaction and for control of the oligomeric state of the nucleoprotein. Structural comparison of this heterodimer with other members of the filovirus family allowed us to find conserved and essential atomic features that will facilitate understanding of the virus life cycle and the rational design of antivirals.

Citing Articles

Structural basis for Ebola virus nucleocapsid assembly and function regulated by VP24.

Fujita-Fujiharu Y, Hu S, Hirabayashi A, Takamatsu Y, Ng Y, Houri K Nat Commun. 2025; 16(1):2171.

PMID: 40064872 PMC: 11894184. DOI: 10.1038/s41467-025-57236-4.


To be or not to be phosphorylated: understanding the role of Ebola virus nucleoprotein in the dynamic interplay with the transcriptional activator VP30 and the host phosphatase PP2A-B56.

Kamper L, Kuhl I, Vallbracht M, Hoenen T, Linne U, Weber A Emerg Microbes Infect. 2024; 14(1):2447612.

PMID: 39726359 PMC: 11727051. DOI: 10.1080/22221751.2024.2447612.


How does the polymerase of non-segmented negative strand RNA viruses commit to transcription or genome replication?.

Kleiner V, Fearns R J Virol. 2024; 98(8):e0033224.

PMID: 39078194 PMC: 11334523. DOI: 10.1128/jvi.00332-24.


Impact of Ebola virus nucleoprotein on VP40 virus-like particle production: a computational approach.

Liu X, Stahelin R, Pienaar E Commun Biol. 2024; 7(1):634.

PMID: 38796621 PMC: 11128010. DOI: 10.1038/s42003-024-06300-8.


Ebola and Marburg virus VP35 coiled-coil validated as antiviral target by tripartite split-GFP complementation.

Zinzula L, Mereu A, Orsini M, Seeleitner C, Bracher A, Nagy I iScience. 2022; 25(11):105354.

PMID: 36325051 PMC: 9619376. DOI: 10.1016/j.isci.2022.105354.


References
1.
Winn M, Ballard C, Cowtan K, Dodson E, Emsley P, Evans P . Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 4):235-42. PMC: 3069738. DOI: 10.1107/S0907444910045749. View

2.
Shabman R, Jabado O, Mire C, Stockwell T, Edwards M, Mahajan M . Deep sequencing identifies noncanonical editing of Ebola and Marburg virus RNAs in infected cells. mBio. 2014; 5(6):e02011. PMC: 4222107. DOI: 10.1128/mBio.02011-14. View

3.
Zhu T, Song H, Peng R, Shi Y, Qi J, Gao G . Crystal Structure of the Marburg Virus Nucleoprotein Core Domain Chaperoned by a VP35 Peptide Reveals a Conserved Drug Target for Filovirus. J Virol. 2017; 91(18). PMC: 5571254. DOI: 10.1128/JVI.00996-17. View

4.
Groseth A, Charton J, Sauerborn M, Feldmann F, Jones S, Hoenen T . The Ebola virus ribonucleoprotein complex: a novel VP30-L interaction identified. Virus Res. 2008; 140(1-2):8-14. PMC: 3398801. DOI: 10.1016/j.virusres.2008.10.017. View

5.
Yabukarski F, Lawrence P, Tarbouriech N, Bourhis J, Delaforge E, Jensen M . Structure of Nipah virus unassembled nucleoprotein in complex with its viral chaperone. Nat Struct Mol Biol. 2014; 21(9):754-9. DOI: 10.1038/nsmb.2868. View